Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, doubleblind,-controlled, 2 trial

• Authors: MAURER Marcus; STOBIECKI Marcin; VALERIEVA Anna; HAKL Roman; STAEVSKA Maria T; BOUILLET Laurence; DU-THANH Aurélie; KESSEL Aharon; KIANI-ALIKHAN Sorena; MAGERL Markus; RESHEF Avner; BAEZA Maria Luisa; FAIN Olivier; FARKAS Henriette; GREVE Jens; GUILARTE Mar; JACOBS Joshua S; LI H Henry; LLEONART Ramon; MANNING Michael E; SUSSMAN Gordon L; ANDERSON John; CHAPDELAINE Hugo; COHN Danny M; HAGIN David; KRÁLÍČKOVÁ Pavlína; RITCHIE Bruce; SPADARO Giuseppe; STAUBACH Petra; MICHAEL D Tarzi; YANG William H; JOUVIN Marie-Helene; CRABBÉ Rafael; SIMONE van Leeuwen; CHEN Huaihou; ZHU Li; KNOLLE Jochen; LESAGE Anne; LU Peng; RIEDL Marc A; AYGÖREN-PÜRSÜN Emel
• Year of publication: 2026
• Type: Peer-reviewed scientific article
• Magazine / Source: LANCET HAEMATOLOGY
• MU Faculty or unit: Faculty of Medicine
• web: http://linkinghub.elsevier.com/retrieve/pii/S2352302625003412
• Doi: https://doi.org/10.1016/S2352-3026(25)00341-2
• Keywords: lumbar disc herniation; discectomy timing; surgical outcomes; preoperative symptom duration; cohort study
• Description: Hereditary angioedema is a bradykinin-mediated disorder characterised by recurrent painful swelling attacks. Treatment relies on medications to prevent attacks and on-demand therapies for attack manifestations. Parenteral administration associated with most available on-demand therapies often leads to treatment being delayed or forgone. Deucrictibant is an orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of hereditary angioedema attacks. We aimed to investigate the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema attacks.